Story
The medical-device semifinal of the 9th Zhongguancun International Frontier Technology Competition, part of the 2026 Zhongguancun Forum program, was held at Zhongguancun Medical Device Park on January 20, 2026.
Dr. Chen Dai, Vice President of Migrasome Therapeutics, presented the company’s strategy and progress in migrasome-based clinical diagnostics. The presentation covered a magnetic microparticle chemiluminescence program based on an original migrasome-related target for coagulation risk in patients with severe infections, as well as broader clinical exploration in autoimmune diseases and oncology.
The category's Top 10 projects included Migrasome Therapeutics' Migrasome-Based Diagnostics and Instrumentation Platform.
The event was organized by the Beijing Municipal Science and Technology Commission and the Administrative Commission of Zhongguancun Science Park, with support from several municipal and Zhongguancun organizations. Experts from academia, investment institutions and industry evaluated the projects and offered guidance on financing, policy support, facilities and commercialization.